Cargando…
Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors
PURPOSE: Although temozolomide is widely used in the treatment of childhood central nervous system (CNS) tumors, information on its pharmacokinetic profile in the brain or cerebrospinal fluid (CSF) is sparse. This study aimed at investigating whether measurable and clinically relevant concentrations...
Autores principales: | Büsker, Sören, Jäger, Walter, Poschner, Stefan, Mayr, Lisa, Al Jalali, Valentin, Gojo, Johannes, Azizi, Amedeo A., Ullah, Sami, Bilal, Muhammad, El Tabei, Lobna, Fuhr, Uwe, Peyrl, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054874/ https://www.ncbi.nlm.nih.gov/pubmed/35355137 http://dx.doi.org/10.1007/s00280-022-04424-4 |
Ejemplares similares
-
Clinical Pharmacokinetics and Pharmacodynamics of Cefiderocol
por: Bilal, Muhammad, et al.
Publicado: (2021) -
ETMR-10. EARLY FOCAL RADIOTHERAPY AND TEMOZOLOMIDE FOLLOWING COMPLETE RESECTION APPEAR SUPERIOR TO INTENSIVE CHEMOTHERAPY AND DELAYED RADIOTHERAPY IN CHILDREN WITH EMBRYONAL TUMORS WITH MULTILAYERED ROSETTES (ETMR)
por: Mayr, Lisa, et al.
Publicado: (2020) -
Improved Long-Term Survival of Patients with Recurrent Medulloblastoma Treated with a “MEMMAT-like” Metronomic Antiangiogenic Approach
por: Slavc, Irene, et al.
Publicado: (2022) -
Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients
por: Guntner, Armin Sebastian, et al.
Publicado: (2020) -
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial
por: Peyrl, Andreas, et al.
Publicado: (2023)